EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models

• Published in: Frontiers in cellular and infection microbiology Vol. 12; p. 1078504
• Main Authors: Guo, Yanru, Kamara, Saidu, Zhang, Jing, Wen, He, Zheng, Maolin, Liu, Ying, Zhou, Luqi, Chen, Jun, Zhu, Shanli, Zhang, Lifang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.01.2023
• Subjects: affibody molecules; Animals; Cell Line, Tumor; Cell Proliferation; Cellular and Infection Microbiology; EBV; Epstein-Barr Virus Infections - drug therapy; Herpesvirus 4, Human - metabolism; Humans; LMP1; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases - metabolism; nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Carcinoma - virology; Nasopharyngeal Neoplasms - drug therapy; Nasopharyngeal Neoplasms - virology; Neoplasm Recurrence, Local; Ribosomal Protein S6 Kinases, 90-kDa - metabolism; Ribosomal Protein S6 Kinases, 90-kDa - pharmacology; Ribosomal Protein S6 Kinases, 90-kDa - therapeutic use; targeted therapy; Xenograft Model Antitumor Assays; EBV; LMP1; targeted therapy; affibody molecules; nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC), is an Epstein-Barr virus (EBV) associated malignancy most common in Southern China and Southeast Asia. In southern China, it is one of the major causes of cancer-related death. Despite improvement in radiotherapy and chemotherapy techniques, locoregional recurrence an...